ライフサイエンスコーパス: P2X7 receptor

1 rat cortex binding assay) and 15.9 nM (human P2X7 receptor).

2 h-promoting agent (acting at P2Y1, P2Y2, and P2X7 receptors).

3 ophages but not from macrophages lacking the P2X7 receptor.

4 al role in the transcriptional regulation of P2X7 receptor.

5 hought to be characteristic hallmarks of the P2X7 receptor.

6 o cellular responses typically attributed to P2X7 receptor.

7 S) stimulation and ATP signaling through the P2X7 receptor.

8 to be driven by unimpeded activation of the P2X7 receptor.

9 K(+) caused by stimulation of the purinergic P2X7 receptor.

10 a was unimpaired in macrophages deficient in P2X7 receptor.

11 of the extracellular loop of the full-length P2X7 receptor.

12 hly sensitive to that stimulated through the P2X7 receptor.

13 ing of a large pore at the recombinant human P2X7 receptor.

14 739 demonstrates that the tracer engages the P2X7 receptor.

15 reatment for epilepsy based on targeting the P2X7 receptor.

16 with activation of the ATP-gated ionotropic P2X7 receptor.

17 gonist sensitivity between the human and rat P2X7 receptors.

18 a(2+) permeability are difficult to apply to P2X7 receptors.

19 asses that selectively target P2X1, P2X3, or P2X7 receptors.

20 human embryonic kidney cells expressing rat P2X7 receptors.

21 esponse to SCI by activation of low-affinity P2X7 receptors.

22 l lines expressing recombinant human and rat P2X7 receptors.

23 ue-G, and KN-62, demonstrating activation of P2X7 receptors.

24 iate between the two widely used agonists at P2X7 receptors.

25 inhibitor Z-VADfmk, and requires functional P2X7 receptors.

26 with DNA fragmentation, and does not require P2X7 receptors.

27 ifferentially regulated by the activation of P2X7 receptors.

28 of a nonselective permeation pathway by the P2X7 receptor, a phenomenon called "pore formation." How

29 mma disrupts the functionality of purinergic P2X7 receptors, a key step controlling eCB production by

30 Moreover, in vitro blockade of the P2X7 receptor abrogates the levels of these cytokines.

31 till convincing evidence indicating that the P2X7 receptor activates a separate pathway that permeate

32 ular Ca(2+) increase and K(+) depletion, the P2X7 receptor activates other peculiar responses whose m

33 e investigated whether LTB4 is produced upon P2X7 receptor activation and examined whether LTB4 modul

34 P2X7 receptor activation induces the release of differen

35 Evidence also shows that P2X7 receptor activation is linked to elevated expressio

36 These results indicate that P2X7 receptor activation leads to LTB4 formation, which

37 P2X7 receptor activation leads to the release of the pro

38 TLR2 agonists required pannexin-1 and P2X7 receptor activation to stimulate IL-1beta release.

39 investigated for dependence upon caspase-1, P2X7 receptor activation, and loss of membrane asymmetry

40 specific TLR agonists and was accelerated by P2X7 receptor activation.

41 reliant on active caspase-1, pannexin-1, and P2X7 receptor activation.

42 response to ATP concentrations that exclude P2X7 receptor activation.

43 astrocytes with properties characteristic of P2X7 receptor activation: the current was amplified in l

44 o studies have reported parasite death after P2X7-receptor activation in various cell types.

45 found that during a murine model of sepsis, P2X7 receptor activity is important for maintaining elev

46 Likewise, the purinergic P2X7 receptor acts as a direct conduit for Ca(2+)-influx

47 Methods: P2X7 receptor affinity and specificity, pharmacokinetics

48 ll patch clamp studies, exposure to the P2X4/P2X7 receptor agonist 2'3'-O-(4-benzoyl-benzoyl)-adenosi

49 apoptosis in response to treatment with the P2X7 receptor agonist benzoyl-ATP.

50 The P2X7 receptor agonist benzoylbenzoyl-adenosine 5'-tripho

51 receptor agonist ATPgammaS (p<0.001) and the P2X7 receptor agonist BzATP (p<0.001).

52 Acini were stimulated with the P2X7 receptor agonist, (benzoylbenzoyl)adenosine 5' trip

53 ed treatment with lipopolysaccharide and the P2X7 receptor agonist, benzylated ATP, suggesting that n

54 ess functional purinergic receptors and that P2X7 receptor agonists significantly reduce cell numbers

55 n the plasma membrane, but activation of the P2X7 receptor also leads to rapid cytoskeletal re-arrang

56 to be partially mediated by activation of a P2X7 receptor, although hybrid channels cannot be ruled

57 P2Y2, P2Y4, P2Y6, and P2Y12, and at P2X4 and P2X7 receptors), an immunosuppressant (acting at P2Y11),

58 ng mechanisms were prevented by knocking out P2X7 receptor and by the use of specific antagonists.

59 iprotein inflammasome complex, including the P2X7 receptor and caspase-1.

60 However, the roles of P2X7 receptor and intracellular K(+) in IL-1beta secreti

61 Furthermore, we demonstrated that P2X7 receptor and NLRP3 transcription were modulated in

62 -induced cell death in oocytes co-expressing P2X7 receptor and pannexin 1.

63 n experiments with HEK cells, which lack the P2X7 receptor and showed strikingly increased response t

64 S. aureus supernatant was independent of the P2X7 receptor and the essential TLR adaptors MyD88 and T

65 ess a low activation threshold allele of the P2X7 receptor and the P2X7 gene maps to a locus associat

66 derived macrophage cells natively expressing P2X7 receptors and cells transfected with human P2X7 but

67 ry cytokines through mechanisms depending on P2X7 receptors and Px1 HCs.

68 P2X7 receptors and UTP-activated receptors mediated thes

69 g lipin-2 decreases ion currents through the P2X7 receptor, and downstream events that drive IL-1beta

70 2X3, and 10-fold selectivity versus P2X4 and P2X7 receptors, and inhibited collagen-induced platelet

71 anism that involves ATP release, P2 (perhaps P2X7) receptors, and p38 MAPK activation.

72 In this context, P2X7 receptor antagonism could be a promising strategy t

73 X1 receptor antagonist NF449, the purinergic P2X7 receptor antagonist A438079, and azidothymidine (AZ

74 he centrally available, potent, and specific P2X7 receptor antagonist JNJ-47965567 (30 mg/kg) signifi

75 The selective P2X7 receptor antagonist JNJ-47965567 partly replicated

76 ependent receptor occupancy studies with the P2X7 receptor antagonist JNJ-54175446 were obtained in r

77 alf-maximal inhibitory concentration) of the P2X7 receptor antagonist JNJ-64413739 is 1.0 +/- 0.2 nM

78 f both cytokines was blocked completely by a P2X7 receptor antagonist, oxidized ATP, and partially by

79 reatment of RAW 264.7 macrophages with a P2Z/P2X7 receptor antagonist, periodate oxidized adenosine 5

80 ion in oxidized ATP (200 microM); a putative P2X7 receptor antagonist.

81 Other P2X7 receptor antagonists, however, had no effect on LT

82 N'-aryl acyl hydrazides were identified as P2X7 receptor antagonists.

83 ed ATP and the isoquinoline KN-62, two known P2X7 receptor antagonists.

84 y revealed positive immunoreactivity of anti-P2X7 receptor antibodies on non-neuronal cells.

85 ular constituent immunoreactive for specific P2X7 receptor antiserum in the kainate-induced seizure a

86 P2X7 receptors are ATP-gated ion channels that contribut

87 P2X7 receptors are important in the regulation of inflam

88 P2X7 receptors are involved not only in physiological fu

89 P2X7 receptors are nonselective cation channels gated by

90 pressing a rat P2X7 receptor indicating that P2X7 receptors are not involved in stimulation of ATP re

91 TP injection or conditioning lesion, whereas P2X7 receptors are not.

92 ATP-gated P2X7 receptors are prominently expressed in inflammatory

93 pore-forming properties of human and rodent P2X7 receptors are sensitive to perturbations of cholest

94 These data point to the P2X7 receptor as a checkpoint regulator of Tfh cells; th

95 ive stress in ALS microglia and identify the P2X7 receptor as a promising target for the development

96 P2X7 receptors associate with cholesterol-rich lipid raf

97 The ligand-gated ion channel P2X7 receptor attracts special attention due to its wide

98 The P2X7 receptor binds extracellular ATP to mediate numerou

99 nistration of an inhibitor of the purinergic P2X7 receptor blocks the anxiety caused by HFD.

100 f pannexin-1-hemichannel (PNX1) coupled with P2X7-receptor blocks the infection-induced eATP release

101 of fluorescent dyes in many cells expressing P2X7 receptors, but controversy persists as to whether s

102 , in SOD1-G93A microglia, the stimulation of P2X7 receptor by 2'-3'-O-(benzoyl-benzoyl) ATP enhanced

103 onic kidney cells that interact with the rat P2X7 receptor, by affinity purification followed by mass

104 lts demonstrate that the open channel of the P2X7 receptor can allow passage of molecules with sizes

105 itionally, it has been demonstrated that the P2X7 receptor can induce PLA2 activation and arachidonic

106 , we evaluated whether antagonism of the P2Z/P2X7 receptor can influence LPS signaling and expression

107 We further show that activation of P2X7 receptors can lead to the release of tumor necrosis

108 The ATP-gated P2X7 receptor channel (P2X7R) operates as a cytolytic an

109 de during activation by endogenous ATP-gated P2X7 receptor channels, the exogenous bacterial ionophor

110 P2X7 receptors colocalized with anti-caspase-3 antibody

111 we present crystal structures of a mammalian P2X7 receptor complexed with five structurally-unrelated

112 Considering that extracellular ATP through P2X7 receptor constitutes a neuron-to-microglia alarm si

113 rs controlling proliferation, while P2X5 and P2X7 receptors control early differentiation, terminal d

114 cing T-cell activation through the ATP-gated P2x7 receptor controlling Ca2(+) influx.

115 al inhibition of both maternal and offspring P2X7 receptors could reverse the compromised brain devel

116 Patch clamp analysis of P2X7 receptor currents carried by Na(+) and N-methyl-D-g

117 eptic mice displayed enhanced agonist-evoked P2X7 receptor currents, and synaptosomes from these anim

118 In P2X7 receptor deficient mice (P2rx7-/-), the social inte

119 fficient to induce motor neuron death by the P2X7 receptor-dependent activation of the Fas pathway.

120 TLR agonists induced P2X7 receptor-dependent IL-1beta release in both monocyt

121 ion by means of its fimbriae in a purinergic P2X7 receptor-dependent manner.

122 The generation of prothrombotic MPs required P2X7 receptor-dependent production of ROS leading to inc

123 e data suggest that PDI regulates a critical P2X7 receptor-dependent signaling pathway that generates

124 c receptor P2X, ligand-gated ion channel, 7 (P2X7 receptor; encoded by P2rx7) induced activation (dec

125 mat binds to the P2rx7 enhancer and promotes P2X7 receptor expression in the absence of HDAC3.

126 These results were relevant in vivo since P2X7 receptor expression was upregulated in a P. gingiva

127 ymocyte survival and is required to suppress P2X7 receptor expression.

128 cted but potentially important points in the P2X7 receptor field.

129 tative measures of the Ca(2+) current of the P2X7 receptor for the first time, and suggest that the c

130 P2X7 receptors form large ion channels when activated by

131 study, we investigate the effect of loss of P2X7 receptor function on retinal structure and function

132 Lack of P2X7 receptor function reduced phagocytosis at all ages

133 nalgesic tolerance, without affecting normal P2X7 receptor function.

134 no and carboxyl termini in the regulation of P2X7 receptor gating.

135 Our in vitro findings revealed that P2X7 receptor has a dual role, being critical not only f

136 Overall, we conclude that the P2X7 receptor has a role in periodontal immunopathogenes

137 he present study suggests that targeting the P2X7 receptor has anticonvulsant and possibly disease-mo

138 The P2X7 receptor has since been shown to play a leading rol

139 lly relevant strategy by which to antagonize P2X7 receptors has yet, to the best of our knowledge, be

140 ular ATP signaling, particularly through the P2X7 receptor, has considerable translational potential,

141 sue, followed by activation of high-affinity P2X7 receptors, has previously been implicated in second

142 idely distributed in the nervous system, and P2X7 receptors have roles in neuropathic pain and in the

143 normal mice or those in which genes for the P2X7 receptor, IL-1beta, IL-1alpha, IL-18, or caspase-1

144 pothesized that the ATP-activated macrophage P2X7 receptors implicated in nucleotide-mediated macroph

145 Our data confirm the importance of the P2X7 receptor in ATP-stimulated cell death and IL-1beta

146 We expressed the rat P2X7 receptor in human embryonic kidney cells and measur

147 f a ligand gated ion channel, the purinergic P2X7 receptor in MIA-induced autism-like behavioral and

148 ent study shows that loss of function of the P2X7 receptor in mice induces retinal changes representi

149 Therefore, we investigated the role of the P2X7 receptor in response to crystal-induced cytokine re

150 ivo characteristics suitable for imaging the P2X7 receptor in the brain and warrants further studies

151 an (18)F-labeled PET ligand for imaging the P2X7 receptor in the brain.

152 This report implicates the P2Z/P2X7 receptor in the control of protein kinase cascades

153 element in the transcriptional regulation of P2X7 receptor in the nervous system.

154 ed cell death, indicating a primary role for P2X7 receptors in both of these effects.

155 The importance in vivo of P2X7 receptors in control of virulent Mycobacterium tube

156 annels mediate innate immunity downstream of P2X7 receptors in human macrophages.

157 study demonstrated functional expression of P2X7 receptors in non-neuronal but not in small diameter

158 In the present study, the expression of P2X7 receptors in non-neuronal cells and neurons isolate

159 showed that prolonged agonist activation of P2X7 receptors in non-neuronal cells did not lead to cyt

160 Modulation of P2X7 receptors in non-neuronal cells might have impact o

161 In addition, the released ATP activates P2X7 receptors in satellite cells that enwrap each DRG n

162 lso acted as a selective antagonist of human P2X7 receptors in several functional studies.

163 le for P2X2 and P2Y1, but not P2X1, P2X3, or P2X7, receptors in injury-induced ERK activation.

164 HDAC3-deficient DP thymocytes upregulate the P2X7 receptor, increasing sensitivity to ATP-induced cel

165 ophages; however, only monocytes also showed P2X7 receptor-independent release of mature IL-1beta.

166 K293 cells and HEK293 cells expressing a rat P2X7 receptor indicating that P2X7 receptors are not inv

167 Here, we show for first time that P2X7 receptor induces the release of CD14 in extracellul

168 In addition, the sustained activation of P2X7 receptors inhibited cell-to-cell electrotonic trans

169 onists, compounds with ancillary P2X4 and/or P2X7 receptor inhibition were discovered.

170 le translational potential, given that novel P2X7-receptor inhibitors are already available for clini

171 es through mediation of integrin beta(3) and P2X7 receptor interactions in primed cells.

172 The P2X7 receptor is a non-selective cation channel activate

173 IL-1beta in the brain, and antagonism of the P2X7 receptor is a novel therapeutic strategy to dampen

174 The P2X7 receptor is a trimeric channel with three binding s

175 The P2X7 receptor is a trimeric ligand-gated ion channel act

176 The P2X7 receptor is an adenosine triphosphate-gated ion cha

177 The P2X7 receptor is an ATP-gated ion channel known for its

178 The P2X7 receptor is an ATP-sensitive ligand-gated cation ch

179 The P2X7 receptor is an ionotropic receptor predominantly ex

180 well as wild-type mice, suggesting that the P2X7 receptor is not required for control of pulmonary M

181 previous reports, our results indicate that P2X7 receptor is not required for crystal-induced CKD an

182 The P2X7 receptor is unique in having an intracellular carbo

183 In our study, we show that the ATP-gated P2X7 receptor is upregulated in experimental epilepsy an

184 ad to a better understanding of not only the P2X7 receptor itself but also some important physiologic

185 unctional studies, our data suggest that the P2X7 receptor itself constitutes a lipid-composition dep

186 xogenous LTB4, and macrophages obtained from P2X7 receptor knockout mice eliminated L. amazonensis wh

187 tochemical studies on human lymphoid tissue, P2X7 receptor labeling was observed within discrete area

188 V-2 infection may trigger hyperactivation of P2X7 receptors leading to NLRP3 inflammasome stimulation

189 at hyperoxia induces K(+) efflux through the P2X7 receptor, leading to inflammasome activation and se

190 indings suggest a noxious mechanism by which P2X7 receptor leads to enhanced oxidative stress in ALS

191 Activation of the P2X7 receptor leads to opening of the characteristic dye

192 ptosomes from these animals showed increased P2X7 receptor levels and altered calcium responses.

193 tivation by mithramycin A reduced endogenous P2X7 receptor levels in primary cultures of cortical neu

194 P2X7 receptor levels were increased in hippocampal subfi

195 re exist functional data suggesting that the P2X7 receptor may also activate other intracellular sign

196 Gln have >85% loss of 'pore' function of the P2X7 receptor measured by ATP-induced ethidium uptake.

197 Several observations indicated that the P2X7 receptor mediated this effect.

198 infection inhibits extracellular-ATP (eATP)/P2X7-receptor mediated cell death in gingival epithelial

199 gonists of PLA(2) and Cl(-) channels abolish P2X7 receptor-mediated current facilitation, membrane pe

200 lagellin proceeds normally in the absence of P2X7 receptor-mediated cytoplasmic K(+) perturbations.

201 ctivation of the NLRP3 inflammasome utilizes P2X7 receptor-mediated potassium efflux.

202 The P2X7 receptor mediates extracellular ATP signaling impli

203 In summary, these data suggest that the P2Z/P2X7 receptor modulates LPS-induced macrophage activatio

204 one (compound 35), were found to have robust P2X7 receptor occupancy at low doses in rat with ED50 va

205 Stimulation of the P2X7 receptor of NOD mice resulted in more pronounced sh

206 the agonist-gated Ca(2+) flux of recombinant P2X7 receptors of dog, guinea pig, human, monkey, mouse,

207 3cr1-deficient MPs express increased surface P2X7 receptor (P2RX7), which stimulates IL-1beta maturat

208 Increased P2X7 receptor (P2X7R) activity is a cardinal feature of

209 The P2X7 receptor (P2X7R) belongs to the P2X family of ATP-g

210 n1 (Panx1) channel and purinergic ionotropic P2X7 receptor (P2X7R) blockers.

211 Agonist properties of the P2X7 receptor (P2X7R) differ strikingly from other P2X r

212 the pore of the monovalent cation-selective P2X7 receptor (P2X7R) expands to accommodate large molec

213 Here, we demonstrate that stimulation of the P2X7 receptor (P2X7R) for ATP alkalinizes lysosomes in c

214 The P2X7 receptor (P2X7R) for ATP is a therapeutic target fo

215 nine (Arg, R) at codon 460 of the purinergic P2X7 receptor (P2X7R) has repeatedly been associated wit

216 The proposed presence of P2X7 receptor (P2X7R) in neurons has been the source of

217 The P2X7 receptor (P2X7R) is a promising target for neuroinf

218 Among all P2X receptors, the P2X7 receptor (P2X7R) is a well-defined therapeutic targ

219 The P2X7 receptor (P2X7R) is an adenosine triphosphate-gated

220 The P2X7 receptor (P2X7R) is an ATP-gated cation channel tha

221 The P2X7 receptor (P2X7R) is an ATP-gated nonselective catio

222 The ATP-gated ionotropic P2X7 receptor (P2X7R) modulates glial activation, cytoki

223 The P2X7 receptor (P2X7R) orchestrates neuroinflammation, an

224 We find that the P2X7 receptor (P2X7R) plays an important role in LL-37 i

225 The P2X7 receptor (P2X7R) regulates many cellular functions.

226 previously that activation of the purinergic P2X7 receptor (P2X7R) triggers sAPPalpha shedding from n

227 ctive pores similar to those elicited by the P2X7 receptor (P2X7R), an ATP-gated cation channel expre

228 Stimulation of the P2X7 receptor (P2X7R), an ATP-gated ion channel, trigger

229 ling purinergic receptors, predominantly the P2X7 receptor (P2X7R), via an ATP analog initiate innate

230 We recently reported that P2X7 receptor (P2X7R)-induced activation of caspase-1 in

231 was inhibited by a specific inhibitor of the P2X7 receptor (P2X7R).

232 enin release (>/=2-fold), whereas purinergic P2X7 receptors (P2X7R) blockade with A740003 (3 microM)

233 involving autocrine activation of ionotropic P2X7 receptors (P2X7R) by ATP.

234 tes/macrophages in response to activation of P2X7 receptors (P2X7R) by extracellular ATP.

235 gh the inhibition of the P2X purinoceptor 7 (P2X7) receptor (P2X7R), an ATP-gated ion channel, and a

236 Blockading P2X7 receptor(P2X7R) provides neuroprotection toward var

237 P2X7 receptors (P2X7Rs) affect many epithelial cell func

238 Purinergic ionotropic P2X7 receptors (P2X7Rs) are closely associated with exci

239 P2X7 receptors (P2X7Rs) are ligand-gated ion channels se

240 P2X7 receptors (P2X7Rs) are unique purinergic receptors

241 o ethidium (Etd(+)) and Ca(2+) by activating P2X7 receptors (P2X7Rs) that open pannexin hemichannels

242 tracellular ATP binds to and signals through P2X7 receptors (P2X7Rs) to modulate immune function in b

243 we found that infection with H37Ra inhibits P2X7 receptor (P2XR) signals and that CsA restores P2XR

244 Antagonizing the ATP-dependent P2X7 receptor pathway of inflammasome activation signifi

245 We demonstrate that ATP acting via the P2X7 receptor pathway promotes a Th17 polarizing microen

246 sion of the death signal requires functional P2X7 receptors, pointing to a role for these receptors i

247 eveal cholesterol as a negative regulator of P2X7 receptor pore formation, protecting cells from P2X7

248 Taken together, these data suggest that the P2X7 receptor promotes inflammatory infiltrates, proinfl

249 MoAb was used to immunoprecipitate the human P2X7 receptor protein, and in immunohistochemical studie

250 BM chimeras revealed that P2X7 receptor prothrombotic function was present in both

251 Here we show that P2X7 receptors provide a route for excitatory amino acid

252 The P2X7 receptor regulates cell growth through mediation of

253 -1 hemichannels to the immune synapse, while P2X7 receptors remain uniformly distributed on the cell

254 +/- 0.6 nM at the recombinant human and rat P2X7 receptor, respectively, and the binding affinity is

255 Enhancement of P2X7 receptor responses may be useful in pathogen cleara

256 Here we show that the ATP-gated ionotropic P2X7 receptor restricts the expansion of aberrant Tfh ce

257 Activation of the P2X7 receptor resulted in its dephosphorylation.

258 ATP stimulation of cell surface P2X7 receptors results in cytolysis and cell death of ma

259 P2X7 receptors (Rs) constitute a subclass of ATP-sensiti

260 tly, we identified a novel pathway involving P2X7 receptor scavenger function expressed on ocular imm

261 Whole-cell recordings from cells expressing P2X7 receptors showed that this markedly reduced subsequ

262 as been suggested previously that purinergic P2X7 receptor signaling is critical for crystal-induced

263 ith cellular activation typically induced by P2X7 receptor signaling.

264 Thus, we have identified a P2X7 receptor signalling complex, some members of which

265 Dissipation of ATP by CD39 reduced P2X7 receptor stimulation and thereby suppressed baselin

266 Because P2X7 receptor stimulation can rapidly activate caspase f

267 We also found that, following P2X7 receptor stimulation, the phosphorylation of ERK1/2

268 ere shed preferentially from NOD cells after P2X7 receptor stimulation.

269 Here we show P2X7 receptor subunits on presynaptic motor nerve termin

270 However, whether and how P2X7 receptor suppression protects blood-brain barrier(B

271 lar amounts of ATP, activation of purinergic P2X7 receptors, sustained rise in intracellular calcium,

272 uncovered a novel site (Y382-384) within the P2X7 receptor that can be targeted to blunt the developm

273 drial ATP production, and stimulate P2X4 and P2X7 receptors that elicit interleukin 2 production and

274 nt set of mechanisms, not requiring ART-2 or P2X7 receptors that more slowly induce cell death.

275 ce, and that these groups act as ligands for P2X7 receptors that then induce rapid cell death.

276 iggers, through activation of the purinergic P2X7 receptor, the formation of the inflammasome, a mult

277 m channels is less potent than inhibition of P2X7 receptors, there may be significant inhibition of s

278 ctivates the inflammasome via the purinergic P2X7 receptor to cause inflammation and hyperoxic acute

279 agonists plus ATP, the latter activating the P2X7 receptor to decrease intracellular K+ levels.

280 ns circumvent the requirement of ATP and the P2X7 receptor to induce caspase-1 activation via Nlrp3.

281 OD1-G93A mice and SOD1-G93A mice lacking the P2X7 receptor to investigate the effects of both pharmac

282 ease, which in turn activated the purinergic P2X7 receptor to mediate cytotoxicity.

283 cells, the activation of M3AChRs stimulates P2X7 receptors to increase [Ca2+]i and protein secretion

284 ing pathways that overlap with those used by P2X7 receptors to increase [Ca2+]i, but they also use si

285 to become self sustaining through action of P2X7 receptors to open pannexin hemichannels and then co

286 they also use signaling pathways not used by P2X7 receptors to stimulate protein secretion.

287 ed SAPK activation could be recapitulated in P2X7 receptor-transfected HEK293 cells, but not in wild-

288 d origin show robust expression of ATP-gated P2X7 receptors, two-transmembrane ion channels permeable

289 strate that ATP signaling through macrophage P2X7 receptors uncouples the thioredoxin (TRX)/TRX reduc

290 Finally, we found that Sp1 mediates P2X7 receptor up-regulation in neuroblastoma cells cultu

291 lonal antibody (MoAb) specific for the human P2X7 receptor was generated in mice.

292 P2X7 receptor was higher expressed in murine atheroscler

293 Interestingly, we found that the P2X7 receptor was upregulated in the chronic phase of EA

294 blue G (BBG), best known as an antagonist of P2X7 receptors, was found to inhibit voltage-gated sodiu

295 Using macrophages lacking the P2X7 receptor, we observed that ATP was not able to redu

296 P2X7 receptors were expressed in the necrotic center of

297 l and intermediate layers, and both P2Y2 and P2X7 receptors were in the periderm.

298 ly as the channel opened, in contrast to the P2X7 receptor where the NMDG permeability develops over

299 vation of macrophage surface-associated P2Z (P2X7) receptors, which are one of the purinergic recepto

300 PET ligands for the P2X7 receptor will not only be valuable to assess centra